ACTG A randomized treatment-naive individuals to tenofovir-emtricitabine ( TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or. This article reviews some of the differences in initial therapies for HIV infection. ACTG Shows Abacavir/lamivudine and Tenofovir/emtricitabine Provide Similar HIV Suppression at Low Viral Loads.
|Published (Last):||23 January 2013|
|PDF File Size:||4.68 Mb|
|ePub File Size:||2.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
Treatment guidelines Starting treatment Side-effects Adherence Drug interactions and pharmacokinetics Treatment for women Resistance Changing treatment 52202 interruptions Treatment-experienced people New and experimental HIV treatments Long-acting HIV treatment Treatment simplification strategies Outcomes and prognosis The search for a cure Bad science and bogus treatments.
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A
In this protocol-specified secondary analysis of ACTG A and its viral load substudy, we found no significant difference in early viral load change between the NRTI arms, including in the high viral load stratum.
NAM recommends checking whether this is the most current information when making decisions that may affect your health.
The association analysis is based on data collected post-randomization and restricted to those who were able to return for their Week 4 viral load sample. Ethics Approval was obtained from each participating sites’ institutional review board for the main study and the substudy.
Conclusions — Comparing Atazanavir and Efavirenz Here are some of the conclusions that the ACTG team arrived at when comparing atazanavir-ritonavir to efavirenz: Although no significant difference appeared in any of the paired comparisons between treatment combinations, ACTG was not able to formally demonstrate “equivalence” for any comparison. Author information Copyright and License information Disclaimer.
If you have or suspect you may have a health problem, consult your health care provider. However, previous studies have shown that single early viral load measurements can be used as surrogates for the more complex sampling and modeling involved in estimating the phases of decay.
Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: Abacavir in Kivexa was associated with an increased risk of elevated lipids in the blood whether efavirenz or atazanavir-ritonavir was used.
Both regimens seemed equally effective. In ACTGhypersensitivity testing was not part of the protocol and so there was an increased risk of suspected hypersensitivity reactions among people assigned to receive Kivexa, which contains abacavir. There were some significant differences in time to adverse events and regimen changes.
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202
Our award-winning axtg of booklets, with each title providing a comprehensive overview of one aspect of living with HIV. Similarly, clinical trials that compare integrase inhibitor- to non-integrase inhibitor-based regimens invariably show a faster viral load decline in the integrase treatments, yet the ultimate study outcomes may be comparable.
See, however, the discussion of equivalence, below.
ACTG was a blinded clinical trial in which treatment-naive patients were randomised to begin one of four different antiretroviral combinations.
In Januaryan interim analysis found that participants who entered ACTG with a high viral load more thancopies and who also received Kivexa were at increased risk for treatment failure.
Italian study shows growth in heart and kidney problems in people living with HIV 28 December HR for grade 3 or 4 event of 1. Study Details The average profile of participants at the start of the study acty as follows: However, hypersensitivity testing via a simple blood test is increasingly done by doctors before abacavir is prescribed, so the risk of this reaction is now very, very low in most high-income countries.
Baseline characteristics actt balanced between subjects randomized to each of the four study regimens within the substudy data not shown.
We found a smaller week 4 virologic response was associated with an increased risk for subsequent virologic failure. Additionally, for the early viral load substudy, the sample size was relatively small and we did not sample sufficient timepoints to calculate Phase 1 and Phase 2 decay rates. In summary, we have shown that smaller four-week decline in viral load was associated with a higher rate of subsequent virologic failure.
ACTG 5202 — Effectiveness of Different Treatments
Abacavir Phase 2 Clinical Team. CollierMD, 5 Margaret A. Tierney is a paid member of a Actv Monitoring Committee for a Tibotec-sponsored hepatitis C drug study. A Randomized Multicenter Trial. Particularly useful when looking for information on a specific issue, rather than exploring a wider topic.
During the study, kidney health generally improved regardless of the regimen used.